On the stock market since 2013, it operates in the world of health and science. It has 3,074 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
No real growth (-2% a year). Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 65% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $311.4M in the vault; even if every debt were paid off, $93.0M would remain.
It pays out $1.93 per share each year — regular cash for whoever holds the stock.
A loss of $110.7M against $882.9M in annual sales. And on top of that, sales fell from the year before.
The sales tempo runs behind the sector. Council score: 2/10.
The weight of investors positioned for a fall can be felt in the market. Council score: 2/10.
On our five-subject report card, TCHBF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: TCHBF has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.